# Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

> **NCT00435448** · PHASE3 · TERMINATED · sponsor: **Threshold Pharmaceuticals** · enrollment: 480 (—)

## Conditions studied

- Benign Prostatic Hyperplasia
- Enlarged Prostate

## Interventions

- **DRUG:** Lonidamine

## Key facts

- **NCT ID:** NCT00435448
- **Lead sponsor:** Threshold Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 480 (—)
- **Last updated:** 2009-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00435448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00435448, "Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00435448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*